738.8%—that’s the compound annual growth rate Maximus, a Santa Monica-based telehealth company, needed to achieve between 2022 and 2025 to land at #7 on the Financial Times list of The Americas’ Fastest Growing Companies 2026. While headline-grabbing growth is common in the telehealth sector post-pandemic, Maximus’s trajectory isn’t simply a story of riding the wave; it’s a case study in how targeted specialization—specifically, “performance medicine”—can unlock exponential returns even within a crowded market. Follow the money, and you’ll find a company betting heavily on preventative care and quantifiable results, a strategy that’s clearly resonating with both investors and, crucially, customers willing to pay a premium.
The Performance Medicine Premium
The Financial Times list, compiled in partnership with Statista Inc., ranks companies by their absolute revenue growth rate over three years. While the top spot went to a Brazilian fintech firm with a 987.2% CAGR, Maximus’s 738.8% growth places it firmly among the elite, outpacing many better-known telehealth names. This isn’t accidental. Maximus isn’t offering general virtual check-ups; it focuses on “performance medicine,” a blend of telehealth, biomarker analysis, and personalized interventions aimed at optimizing physical and cognitive function. This translates to services like hormone optimization, longevity protocols, and cognitive enhancement—areas where consumers are increasingly willing to self-fund, even without full insurance coverage. The average cost of a Maximus program starts at $500 per month, significantly higher than the $60-$100 average for a typical telehealth consultation, according to a recent report by the American Telemedicine Association.
Beyond the Pandemic Bump: Sustained Demand
Many telehealth companies experienced a surge in demand during the COVID-19 pandemic, followed by a correction as in-person care resumed. Maximus, however, appears to be demonstrating sustained growth beyond this initial bump. Revenue figures released alongside the Financial Times ranking show a consistent upward trend: 215% growth in 2023, 280% in 2024, and a projected 243% for 2025. This suggests that the company’s growth isn’t solely attributable to pandemic-driven demand, but rather to a growing consumer base actively seeking out its specialized services. Competitors like Teladoc Health and Amwell, while still industry giants, have reported more modest growth rates in recent quarters—Teladoc’s 2024 revenue growth was 11%, and Amwell’s 15%—indicating a potential shift in consumer preference towards more focused, personalized telehealth solutions.
Based on the original Yahoo Finance report.
The Data-Driven Approach to Acquisition
Maximus’s marketing strategy is as data-driven as its medical protocols. The company heavily utilizes targeted online advertising, focusing on demographics interested in biohacking, longevity, and peak performance. This contrasts with the broader marketing approaches of larger telehealth providers. A key component of their acquisition strategy is the emphasis on quantifiable results. Maximus actively tracks and reports on patient outcomes, using biomarker data to demonstrate the effectiveness of its programs. This data is then used in marketing materials, creating a feedback loop that reinforces the perception of value and drives further demand. This approach is particularly effective in attracting a demographic that values self-optimization and is accustomed to tracking personal metrics.
What This Means for Your Wallet
The success of Maximus signals a potential fragmentation within the telehealth market. While general telehealth services will likely remain a staple for basic healthcare needs, specialized providers focusing on preventative and performance medicine are poised to capture a growing share of the market—and a larger share of consumers’ healthcare spending. This means consumers will increasingly face a choice: a low-cost, convenient option for routine care, or a premium-priced, data-driven approach focused on optimizing health and performance. The question investors should be asking now is whether Maximus can maintain its growth trajectory as it scales, and whether larger players will attempt to replicate its specialized model through acquisition or internal development. For consumers, the key takeaway is to carefully evaluate your healthcare needs and determine whether the potential benefits of performance medicine justify the higher cost. Will we see a broader industry shift towards outcome-based telehealth, and will insurance companies begin to cover these specialized services? That’s the metric to watch in the coming year.
